Some reports had suggested that the anti-cancer effects of aurora kinase inhibitors may depend on p73 activation in addition to p53 activation [39], [40] or that a p73 response may even replace a p53 response in p53-deficient cells [32]. The gene discussed is TP53; the disease is cancer.